Loeb Cuts Kenvue Stake by 64% as Kimberly-Clark Deal Looms

Daniel Loeb's Third Point hedge fund has dramatically reduced its position in Kenvue Inc., slashing holdings by 64% during the fourth quarter of 2025, according to regulatory filings. The billionaire investor trimmed his stake from 9.0 million shares to 3.25 million shares, signaling a significant shift in conviction regarding the consumer health company even as the firm navigates substantial restructuring and approaches a major acquisition milestone.

The Numbers Behind the Exit

Loeb's decision to substantially pare back his Kenvue holdings marks a notable departure from the investor's earlier commitment to the company. The 64% reduction in share count represents one of Third Point's most significant portfolio moves in recent quarters, particularly striking given Kenvue's prominent position in the consumer staples sector.

The company, home to iconic brands including Tylenol, Listerine, Neutrogena, and Johnson's baby care products, is simultaneously undertaking a comprehensive restructuring initiative. Key metrics from the company's transformation efforts include:

• 3.5% workforce reduction across the organization
• $250 million in restructuring charges expected throughout 2026
• Streamlined operational footprint targeting improved profitability and efficiency

These cost-cutting measures underscore management's focus on operational excellence amid broader market pressures facing consumer health companies. However, they also signal ongoing challenges that may have influenced Loeb's decision to trim exposure.

Market Context: A Transformative Acquisition

Loeb's retreat from Kenvue comes amid a transformative period for the company. Kimberly-Clark Corporation announced its intention to acquire Kenvue in an all-cash transaction valued at $48.7 billion on an enterprise value basis, representing a significant consolidation within the consumer health and personal care sectors.

The deal structure reflects the strategic importance both companies place on combining complementary portfolios. For Kimberly-Clark ($KMB), the acquisition offers immediate scale in premium consumer health brands and would create a formidable competitor in over-the-counter medications, oral care, and skincare markets. The transaction is projected to close during the second half of 2026, contingent on regulatory approval—a critical variable given current antitrust scrutiny affecting major corporate combinations.

The consumer health sector has faced structural headwinds in recent years, including:

• Increasing pricing pressure from retailers and pharmacy chains
• Evolving consumer preferences favoring digital health and telehealth alternatives
• Consolidation trends concentrating market power among larger players
• Supply chain normalization reducing pandemic-era demand surges

Loeb's significant reduction in Kenvue holdings may reflect concerns about the trajectory of the business between now and deal closure, potential regulatory obstacles, or simply a reallocation of capital toward other opportunities offering more attractive risk-reward profiles.

Investor Implications and What's At Stake

For Kenvue shareholders, Loeb's exit carries mixed signals. On one hand, the $48.7 billion enterprise value acquisition price was viewed by many analysts as providing price certainty and avoiding prolonged uncertainty. However, the substantial length of the regulatory review period—extending into H2 2026—creates extended execution risk that may be concerning investors.

The billionaire investor's departure also raises questions about the fundamental health of Kenvue's standalone business. Loeb built Third Point's reputation on identifying compelling value opportunities and engaging constructively with management; his exit suggests skepticism about near-term momentum or the company's ability to maximize shareholder value before the Kimberly-Clark transaction closes.

For potential investors, key considerations include:

• Regulatory risk: Antitrust authorities may impose divestitures or conditions that reduce deal value
• Deal timing: The extended closure window (H2 2026) extends uncertainty and opportunity cost for shareholders
• Restructuring execution: Successfully implementing the 3.5% workforce reduction while maintaining operational continuity
• Brand momentum: Maintaining market share and pricing power in competitive consumer health categories

The restructuring charges of $250 million expected in 2026 could pressure near-term profitability, potentially creating additional headwinds during the critical period before deal closure. This operational backdrop likely factored into Loeb's decision-making calculus.

Looking Ahead: The Endgame

As Kenvue moves through 2026, all eyes will be on regulatory progression and operational execution. The company must demonstrate stability across its portfolio of global brands while managing the psychological and organizational challenges of operating under acquisition while simultaneously rightsizing its workforce.

Loeb's reduced exposure—dropping from one of Kenvue's most significant activist investors to a much smaller position holder—signals a recalibration of risk tolerance. Whether this proves prescient or premature will depend on how smoothly the Kimberly-Clark acquisition proceeds and whether regulatory bodies approve the combination without material disruptions.

For the broader market, the situation highlights the extended timelines and execution complexity surrounding major consumer staples consolidations in the current regulatory environment, underscoring that even prestigious transactions from creditworthy acquirers carry meaningful risk through closure.